FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Results & Progress
11

My Experience with Zepbound After 3 Months

Petra Harrison·6 months ago
Three months of Zepbound in the books. Here is my honest assessment without the hype. What improved: - Recovery between training sessions (significant) - Sleep quality, particularly deep sleep duration - General sense of wellbeing and mood stability - Skin quality — not something I expected but multiple people commented on it What did not change much: - Strength levels (modest improvement at best) - Body weight (stayed within 2 lbs of starting weight) - Appetite (no noticeable change either direction) Timeline of effects: the first 2-3 weeks were essentially a placebo-free zone. I felt nothing and wondered if I was wasting my time. Week 3-4 is when the sleep improvements kicked in. By week 6, recovery benefits were clear. Weeks 8-12 felt like a plateau but in a good way — consistent benefits without escalation. Would I run it again? Yes, after a break. I think cycling is important both for maintaining sensitivity and for verifying that the benefits were actually from Zepbound and not just other lifestyle factors.

Comments (7)

Cameron BakerDEMO·6 months ago

The honest assessment without hype is refreshing. The fact that strength did not change much but recovery improved significantly suggests the GH-related benefits are more about tissue repair than raw hypertrophy. That aligns with the literature.

0
Lennox ChenDEMO·6 months ago

Solid protocol. One suggestion: consider adding HRV tracking if you are not already. It has been the most objective and responsive metric for me during my Zepbound protocol. Changes in HRV preceded subjective improvements by about a week, which gave me early confidence the protocol was working.

2
Darcy HartDEMO·6 months ago

Your point about consistency being more important than optimization really resonates. I wasted weeks early in my Zepbound journey tweaking doses and timing when I should have just picked a reasonable protocol and stuck with it. The best results came when I stopped overthinking and just stayed consistent.

3
Sage CampbellDEMO·6 months ago

This is a great discussion about Zepbound. I want to add that I found morning dosing on an empty stomach gave me noticeably better results than evening dosing. Tried both for 4 weeks each. The difference was subtle but consistent across my tracking metrics.

4
Sasha CortlandDEMO·6 months ago

Your timeline of effects is almost identical to mine. Weeks 1-3 nothing, then sleep improvements, then recovery. I wonder if the sleep improvement is actually driving the recovery benefits rather than a direct tissue repair effect.

0
Dale BanksDEMO·6 months ago

The cycling approach is smart. Receptor desensitization is a real concern with prolonged use. How long of a break are you planning? I have seen recommendations ranging from 4 weeks to equal time off as on.

0
Hayden ArcherDEMO·6 months ago

Skin quality improvement being unexpected is interesting - multiple people report this. Could be related to increased collagen synthesis from elevated GH. It is one of those benefits that takes people by surprise but makes biological sense.

0

Sign in to comment.